Browse the evidence

Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).

If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.

GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.

In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.

Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.

GLP-1 receptor agonists significantly delay gastric emptying and increase residual gastric content, but do not significantly increase the absolute risk of pulmonary aspiration in standard endoscopic procedures.

If you take GLP-1s (like Ozempic or Wegovy) for an endoscopy, expect your stomach to empty slower, but know the risk of lung infection is very low. You likely do not need to stop your medication unless you have specific symptoms or high-risk procedures. Follow extended clear-liquid fasting instructions and use gastric ultrasound if available to ensure safety.

GLP-1 receptor agonists impair colonic preparation and delay capsule transit, increasing the likelihood of inadequate bowel cleansing and the need for repeat colonoscopies.

If you take GLP-1s for a colonoscopy, your bowel prep might be less effective than usual. You may need a more intensive prep regimen (like extended clear liquids or additional laxatives) to ensure the doctor can see clearly. This is common and manageable.

Pharmacological inhibition of angiotensin-converting enzyme (ACE) using enalapril (20 mg/day) during 8 weeks of high-intensity training significantly attenuates exercise-induced increases in lean body mass in healthy adults, while peripheral muscle adaptations and aerobic performance remain unaffected.

If you are taking ACE inhibitors (like enalapril or lisinopril) for blood pressure, be aware that these medications may blunt your muscle growth potential compared to not taking them. This does not mean you cannot build strength or endurance, but your muscle mass gains may be reduced. Focus on consistent training and nutrition, and consult your doctor before making any medication changes.

The ACE I/D genotype is a poor predictor of actual ACE enzyme activity and downstream exercise adaptations because it is in linkage disequilibrium with functional variants and does not consistently correlate with circulating Angiotensin II levels.

Do not rely solely on genetic testing (like ACE I/D) to predict your athletic potential or training response. These tests are often poor predictors of actual performance or muscle growth. Instead, focus on consistent training, proper nutrition, and recovery. If you are curious about your biology, direct measurement of enzyme activity (phenotyping) is more informative than genetic markers alone.

Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.

Stop relying on willpower and calorie counting alone to cure obesity. Your body is biologically fighting to keep its weight at a higher 'set point' through hunger hormones and slowed metabolism. This is not your fault. To achieve lasting weight loss, you likely need medical or surgical interventions that override these biological defenses, as lifestyle changes alone will eventually trigger a rebound effect.

Lower drug prices for semaglutide and tirzepatide could significantly improve their cost-effectiveness, potentially making them competitive with surgical and behavioral interventions.

If drug prices for semaglutide and tirzepatide were reduced, these medications could become cost-effective options for managing class III obesity, potentially offering a non-surgical alternative.

Obesity severity (Class I, II, III) is directly correlated with increased direct medical costs, with Class III obesity costing up to 3.3 times more than normal weight individuals.

Higher obesity classes (II and III) are associated with significantly higher medical costs (up to 3.3x normal weight). This highlights the economic urgency of addressing obesity, especially in higher severity classes, through early intervention.

Intracerebroventricular administration of the GLP-1 receptor agonist Exendin-4(1-32)K-capric acid (Ex-4c) suppresses food intake and body weight gain in mice by directly activating arcuate pro-opiomelanocortin (POMC) neurons.

This research identifies that a specific GLP-1 agonist (Ex-4c) reduces food intake by directly activating POMC neurons in the hypothalamus. The mechanism involves the closure of KATP channels via PKA-dependent signaling. While this is preclinical data in mice, it supports the broader class of GLP-1 agonists used for obesity treatment by confirming a central neural mechanism involving appetite suppression.

Commercially available protein powders in the Hungarian market do not contain significant heavy metal contamination (lead, mercury, cadmium, arsenic) above regulatory safety limits.

If you buy protein powder from a reputable retailer in a regulated market (like the EU or USA), you do not need to worry about dangerous levels of heavy metals like lead or mercury. The products tested in this study were safe. However, because regulation is often voluntary, buying from unknown sources or unregulated 'grey markets' carries a higher risk of contamination.

The lack of a unified definition for resistance exercise (RE) in scientific literature leads to heterogeneous inclusion criteria in systematic reviews, which obscures the true magnitude of effects and impairs the development of evidence-based guidelines.

When evaluating resistance training advice or research, check if the definition of 'resistance' is explicit. If a study or program mixes bodyweight exercises, plyometrics, and weighted lifting without distinguishing them, the results may be less precise. For optimal strength or hypertrophy, ensure the training modality matches your specific goal (e.g., traditional strength vs. plyometrics) rather than assuming all 'resistance' is equal.

Adherence to a vegan diet increases circulating glycine levels despite lower dietary intake, mediated by the reduction of the gut pathobiont Bilophila wadsworthia and its glycine reductase pathway activity.

If you switch to a vegan diet, your body may naturally increase its levels of glycine, an amino acid linked to better insulin sensitivity and metabolic health. This happens not because you eat more glycine, but because your gut bacteria change to stop consuming it. You don't need to supplement glycine; simply adhering to a whole-food vegan diet appears to trigger this beneficial metabolic shift.

Bariatric surgery induces rapid hormonal changes (increased GLP-1, PYY, decreased ghrelin) and bile acid signaling that drive early satiety and metabolic improvements, independent of caloric restriction.

Bariatric surgery works by changing your body's hormones, not just by making your stomach smaller. You will likely feel full faster and have less hunger due to increased GLP-1 and PYY and decreased ghrelin. This biological shift supports your ability to stick to dietary changes.

Enobosarm increases lean body mass but fails to deliver consistent, clinically meaningful functional gains (e.g., stair-climb power) in cancer cachexia patients, leading to regulatory rejection.

Enobosarm was tested for cancer cachexia and successfully increased muscle mass, but it did not improve physical function enough to gain FDA approval. This highlights that muscle size alone does not guarantee functional improvement in sick populations.

S-309309, a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2), demonstrates acceptable safety and tolerability in healthy adults with or without obesity, with no clinically meaningful differences in pharmacokinetics between obese and non-obese individuals.

S-309309 is an experimental oral medication that inhibits MGAT2 to potentially aid weight management. Early trials show it is safe and well-tolerated in both obese and non-obese adults, with no significant drug interactions or cardiac effects observed at tested doses. It is not yet approved for general use.

Bariatric surgery significantly reduces the incidence of obesity-associated cancers and cancer-specific mortality compared to non-surgical controls.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing cancer risk. Discuss surgical options with a specialist if lifestyle changes are insufficient.

High cardiorespiratory fitness (CRF) mitigates or eliminates the 'obesity paradox' in heart failure, meaning overweight patients with high CRF do not have better survival than normal-weight patients with low CRF.

For heart failure patients, being overweight is not inherently protective if you are unfit. High cardiorespiratory fitness (CRF) is the key determinant of survival. Focus on improving your fitness through exercise (like the 6-minute walk test or CPX) rather than just focusing on BMI, as high fitness eliminates the 'obesity paradox' survival advantage.

Tirzepatide improves renal outcomes, including reducing the risk of macroalbuminuria and slowing the decline in estimated glomerular filtration rate (eGFR), in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about kidney health, tirzepatide not only helps control blood sugar and weight but also offers significant protection for your kidneys, reducing the risk of serious renal complications compared to insulin therapy.

Use of GLP-1 receptor agonists is not associated with an increased risk of gastrointestinal cancers and may be associated with reduced risks of colorectal and liver cancers.

Current evidence from large randomized trials indicates that GLP-1 receptor agonists do not increase the risk of gastrointestinal cancers. In fact, they may be associated with a reduced risk of colorectal and liver cancers, particularly in older and obese patients. While these findings are reassuring, cancer was often a secondary endpoint, so long-term monitoring remains important.